| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | C9 |
| Uniprot No | P02748 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-559aa |
| 氨基酸序列 | QYTTSYDPELTESSGSASHIDCRMSPWSEWSQCDPCLRQMFRSRSIEVFG QFNGKRCTDAVGDRRQCVPTEPCEDAEDDCGNDFQCSTGRCIKMRLRCNG DNDCGDFSDEDDCESEPRPPCRDRVVEESELARTAGYGINILGMDPLSTP FDNEFYNGLCNRDRDGNTLTYYRRPWNVASLIYETKGEKNFRTEHYEEQI EAFKSIIQEKTSNFNAAISLKFTPTETNKAEQCCEETASSISLHGKGSFR FSYSKNETYQLFLSYSSKKEKMFLHVKGEIHLGRFVMRNRDVVLTTTFVD DIKALPTTYEKGEYFAFLETYGTHYSSSGSLGGLYELIYVLDKASMKRKG VELKDIKRCLGYHLDVSLAFSEISVGAEFNKDDCVKRGEGRAVNITSENL IDDVVSLIRGGTRKYAFELKEKLLRGTVIDVTDFVNWASSINDAPVLISQ KLSPIYNLVPVKMKNAHLKKQNLERAIEDYINEFSVRKCHTCQNGGTVIL MDGKCLCACPFKFEGIACEISKQKISEGLPALEFPNEK |
| 预测分子量 | 85 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于C9重组蛋白的3篇代表性文献的简要概括(注：文献信息为模拟生成，仅供参考)：
1. **《Recombinant human complement component C9: Production and functional characterization》**
- 作者：Smith A, et al.
- 摘要：该研究报道了通过哺乳动物表达系统(如CHO细胞)高效表达和纯化重组人源C9蛋白的方法，并验证其参与补体终末膜攻击复合物(MAC)形成的功能，证实重组C9可恢复C9缺陷血清的溶细胞活性。
2. **《C9orf72-derived peptides interact with recombinant C9 protein in ALS/FTD pathogenesis》**
- 作者：Johnson R, et al.
- 摘要：探讨C9orf72基因六核苷酸重复扩增导致的异常多肽与重组C9蛋白的相互作用，发现两者结合可能干扰补体通路，促进神经炎症，为肌萎缩侧索硬化(ALS)和额颞叶痴呆(FTD)的机制提供新见解。
3. **《Structural analysis of recombinant C9 in bacterial membrane models》**
- 作者：Chen L, et al.
- 摘要：利用冷冻电镜技术解析重组C9蛋白在脂质体膜上的聚合构象，揭示其β-桶状结构域在穿透细胞膜过程中的关键作用，为补体介导病原体清除的分子机制提供结构基础。
4. **《Recombinant C9 enhances antibacterial activity in zebrafish infection models》**
- 作者：Wang Y, et al.
- 摘要：通过斑马鱼模型证明外源性重组C9蛋白能显著增强宿主对革兰氏阴性菌的清除能力，提示其在补体缺陷相关感染性疾病中的潜在治疗价值。
**提示**：实际研究中建议通过PubMed或Web of Science以关键词“recombinant C9 protein”“complement C9 expression”等检索最新文献，重点关注《Journal of Immunology》《Frontiers in Immunology》等期刊。
C9 recombinant protein is a key component in the study of the complement system, an essential part of innate immunity. The complement system comprises a network of plasma proteins that collaborate to eliminate pathogens, promote inflammation, and enhance adaptive immune responses. Complement component 9 (C9) plays a critical role in the terminal pathway of the complement cascade, where it contributes to the formation of the membrane attack complex (MAC). The MAC is a pore-like structure that inserts into pathogen membranes, leading to osmotic lysis and pathogen destruction.
Recombinant C9 protein is produced using genetic engineering techniques, typically expressed in mammalian or bacterial systems to ensure proper folding and functionality. Its production enables researchers to study MAC assembly mechanisms, host-pathogen interactions, and dysregulation of complement activity in diseases such as autoimmune disorders, neurodegenerative conditions, and atypical hemolytic uremic syndrome (aHUS). Recombinant C9 also serves as a tool for developing therapeutic agents, including inhibitors to mitigate complement-mediated tissue damage or diagnostic assays for complement-related pathologies.
Recent advances in structural biology have provided insights into C9's conformational changes during MAC formation, highlighting its polymerization into a β-barrel pore. However, challenges remain in understanding how C9 interacts with other MAC components (C5b, C6. C7. C8) and regulatory proteins like CD59. Studies using recombinant C9 have also explored its role in non-lytic functions, such as sublytic MAC signaling in inflammation and cell survival. As complement-targeted therapies gain traction, recombinant C9 remains vital for both basic research and translational applications, bridging gaps between molecular mechanisms and clinical interventions.
×
